Overall impact
A (82)

Commentary

Haleon is a leader for overall positive impact. With an 'A' rating of 81.7 for overall impact (95th percentile compared to all companies), Haleon ranks 4th out of 30 industry peers, behind Sanofi, Assembly Biosciences and Astrazeneca, and ahead of Adynxx, Alimera Sciences, Kazia Therapeutics and 23 others. On top material causes for Haleon's industry (Pharmaceuticals & Biotech), Haleon performs well in Decent, Safe Work Opportunities (95.6 score), Child and Maternal Health (94.7), Racial Justice and Civil Rights (81.0) and 6 other causes where it received an 'A' score and performs poorly in Technology Innovation (20.7 score).
Screens
Child safety
EU sanctions list
ILO Conventions
Norges Bank exclusion list
OECD Guidelines
UK sanctions list
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Impact

Cause HLN
Peer rank
Overall impact

Name Rating
Loading...
Screens
Child safety
EU sanctions list
ILO Conventions
Norges Bank exclusion list
OECD Guidelines
UK sanctions list
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Impact trend

Change in rating for overall impact
High rating
Low rating
Average rating
Change in rating
HLN Price
$8.37
Last available end-of-day price. Full disclosure
Revenue
$14.31 billion
Market cap
$38.26 billion
Public/private
Public
Hypothetical historical growth of $10,000
Historical performance
Company
Founded
2021
Employees
25,408
Sector
Healthcare
Industry
Pharmaceuticals & Biotech
Peer group
Drug Manufacturers - Major
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
United Kingdom
Share classes
HLN
Description
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Material causes
Ethos considers the following causes material for Haleon, based on its industry peer group Drug Manufacturers - Major. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.